{"pmid":32353370,"pmcid":"PMC7184986","title":"Letter: Gastrointestinal ACE2, COVID-19 and IBD - opportunity in the face of tragedy?","text":["Letter: Gastrointestinal ACE2, COVID-19 and IBD - opportunity in the face of tragedy?","Gastroenterology","Garg, Mayur","Christensen, Britt","Lubel, John S","32353370"],"journal":"Gastroenterology","authors":["Garg, Mayur","Christensen, Britt","Lubel, John S"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32353370","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1053/j.gastro.2020.04.051","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495623626754,"score":9.490897,"similar":[{"pmid":32303609,"title":"Covid-19 and immunomodulation in IBD.","text":["Covid-19 and immunomodulation in IBD.","The current coronavirus pandemic is an ongoing global health crisis due to covid-19, caused by severe acute respiratory syndrome coronavirus 2. Although covid-19 leads to little or mild flu-like symptoms in the majority of affected patients, the disease may cause severe, frequently lethal complications such as progressive pneumonia, acute respiratory distress syndrome and organ failure driven by hyperinflammation and a cytokine storm syndrome. This situation causes various major challenges for gastroenterology. In the context of IBD, several key questions arise. For instance, it is an important question to understand whether patients with IBD (eg, due to intestinal ACE2 expression) might be particularly susceptible to covid-19 and the cytokine release syndrome associated with lung injury and fatal outcomes. Another highly relevant question is how to deal with immunosuppression and immunomodulation during the current pandemic in patients with IBD and whether immunosuppression affects the progress of covid-19. Here, the current understanding of the pathophysiology of covid-19 is reviewed with special reference to immune cell activation. Moreover, the potential implications of these new insights for immunomodulation and biological therapy in IBD are discussed.","Gut","Neurath, Markus F","32303609"],"abstract":["The current coronavirus pandemic is an ongoing global health crisis due to covid-19, caused by severe acute respiratory syndrome coronavirus 2. Although covid-19 leads to little or mild flu-like symptoms in the majority of affected patients, the disease may cause severe, frequently lethal complications such as progressive pneumonia, acute respiratory distress syndrome and organ failure driven by hyperinflammation and a cytokine storm syndrome. This situation causes various major challenges for gastroenterology. In the context of IBD, several key questions arise. For instance, it is an important question to understand whether patients with IBD (eg, due to intestinal ACE2 expression) might be particularly susceptible to covid-19 and the cytokine release syndrome associated with lung injury and fatal outcomes. Another highly relevant question is how to deal with immunosuppression and immunomodulation during the current pandemic in patients with IBD and whether immunosuppression affects the progress of covid-19. Here, the current understanding of the pathophysiology of covid-19 is reviewed with special reference to immune cell activation. Moreover, the potential implications of these new insights for immunomodulation and biological therapy in IBD are discussed."],"journal":"Gut","authors":["Neurath, Markus F"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32303609","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1136/gutjnl-2020-321269","keywords":["cytokines","inflammation","inflammatory bowel disease"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138491068612608,"score":42.751842},{"pmid":32374032,"title":"Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2 - exploring RAS inhibitors.","text":["Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2 - exploring RAS inhibitors.","We read with interest the article by Taxonera et al outlining a high incidence of diarrhoea in patients with inflammatory bowel disease (IBD) diagnosed with coronavirus disease 19 (COVID-19).[1] The relationship between these symptoms and faecal calprotectin would be interesting to note. In patients without IBD and COVID-19, faecal calprotectin was noted to be higher in patients with continuing than resolved diarrhoea, suggesting intestinal inflammation due to COVID-19.[2].","Aliment Pharmacol Ther","Garg, Mayur","Royce, Simon G","Lubel, John S","32374032"],"abstract":["We read with interest the article by Taxonera et al outlining a high incidence of diarrhoea in patients with inflammatory bowel disease (IBD) diagnosed with coronavirus disease 19 (COVID-19).[1] The relationship between these symptoms and faecal calprotectin would be interesting to note. In patients without IBD and COVID-19, faecal calprotectin was noted to be higher in patients with continuing than resolved diarrhoea, suggesting intestinal inflammation due to COVID-19.[2]."],"journal":"Aliment Pharmacol Ther","authors":["Garg, Mayur","Royce, Simon G","Lubel, John S"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32374032","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/apt.15814","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496348192769,"score":42.016228}]}